

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

1. (Currently Amended) An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF- $\kappa$ B binding sites, wherein the NF- $\kappa$ B binding sites inhibit NF- $\kappa$ B transcriptional activity, wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

2. (Previously presented) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide sequence has two NF- $\kappa$ B binding sites.

3. (Cancelled)

4. (Previously presented) The isolated tolerogenic dendritic cell of claim 1 further comprising a viral vector.

5. (Previously presented) The isolated tolerogenic dendritic cell of claim 4 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

6. (Previously presented) The isolated tolerogenic dendritic cell of claim 5 wherein the viral vector is derived from adenovirus.

7. (Currently amended) A method of producing an isolated tolerogenic dendritic cell comprising (a) propagating an immature isolated dendritic ~~cells~~ cell from a mammalian donor, (b) incubating the immature isolated dendritic ~~cells~~ cell with an oligodeoxyribonucleotide

having at least one NF- $\kappa$ B binding site under conditions wherein the immature isolated dendritic cells ~~cell~~ internalize ~~internalizes~~ the oligodeoxyribonucleotide, wherein the NF- $\kappa$ B binding sites inhibit NF- $\kappa$ B transcriptional activity and (c) culturing ~~said~~ the isolated dendritic ~~cells~~ cell of (b) to produce the isolated tolerogenic dendritic cell.

8. (Cancelled)

9. (Currently amended) The method of claim 7 further comprising incubating the isolated tolerogenic dendritic ~~cells~~ cell in the presence of one or more ~~cytokines~~ cytokine.

10. (Original) The method of claim 9 wherein the cytokine is GM-CSF.

11. (Currently amended) The method of claim 9 further comprising incubating the isolated tolerogenic dendritic ~~cells~~ cell in the presence of TGF- $\beta$ .

12. (Currently amended) The method of claim 7 further comprising infecting said isolated tolerogenic dendritic ~~cells~~ cell with a viral vector.

13. (Original) The method of claim 12 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

14. (Original) The method of claim 13 wherein the viral vector is derived from adenovirus.

15. (Currently amended) A method for enhancing tolerogenicity in a mammalian host comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the immature isolated dendritic cells with an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site under conditions wherein the immature isolated dendritic cells

internalize the oligodeoxyribonucleotide, wherein the NF- $\kappa$ B binding sites inhibit NF- $\kappa$ B transcriptional activity, (c) culturing ~~said~~ the isolated dendritic cells of (b) to produce isolated tolerogenic dendritic cells, and (d) administering said isolated tolerogenic dendritic cells to said host,

wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.

16. (Cancelled)

17. (Currently amended) The method of claim 15 further comprising incubating said isolated tolerogenic dendritic cells in the presence of one or more ~~cytokines~~ cytokine.

18. (Original) The method of claim 17 wherein the cytokine is GM-CSF.

19. (Currently amended) The method of claim ~~[[16]]~~ 15 further comprising incubating said isolated tolerogenic dendritic cells in the presence of TGF- $\beta$ .

20. (Currently amended) The method of claim 15 further comprising infecting said isolated tolerogenic dendritic cells with a viral vector before administering the cells to said host.

21. (Original) The method of claim 20 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

22. (Original) The method of claim 21 wherein the viral vector is derived from adenovirus.

23. (Original) The method of claim 15 further comprising administering FK 506 to the host.

24. (Original) The method of claim 15 further comprising administering cyclosporine A to the host.

25. (Original) The method of claim 15 further comprising administering FK 506 and cyclosporine A to the host.

26. (Currently amended) The method of claim 15 or 20 wherein the isolated tolerogenic dendritic cells are administered to the host intravenously.

27. (Original) The method of claim 15 wherein the host is a transplant host.

28. (Original) The method of claim 15 wherein the host has an inflammatory related disease.

29. (Original) The method of claim 28 wherein the host has arthritis.

30. (Currently amended) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site, wherein the NF- $\kappa$ B binding sites inhibit NF- $\kappa$ B transcriptional activity, wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.

31. (Cancelled)

32. (Original) The kit of claim 30 wherein the tolerogenic dendritic cells further comprise a viral vector.

33. (Original) The kit of claim 32 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

34. (Original) The kit of claim 33 wherein the viral vector is derived from

AP32737 072396.0225  
PATENT

adenovirus.

35-67. (Cancelled)